Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes

Hepatology Communications
Naim AlkhouriEric Lawitz

Abstract

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD is a known risk factor for developing T2D and has a very high prevalence in those with existing T2D. The diabetes spectrum includes several conditions from prediabetes to T2D to insulin-dependent diabetes leading to macrovascular and microvascular complications. Similarly, NAFLD has a histologic spectrum that ranges from the relatively benign nonalcoholic fatty liver to the aggressive form of nonalcoholic steatohepatitis with or without liver fibrosis to nonalcoholic steatohepatitis-cirrhosis leading to end-stage liver disease. The management of T2D has witnessed significant changes over the past few decades with multiple new drug classes entering the treatment algorithm. Unfortunately, there are no U.S. Food and Drug Administration-approved medications to treat NAFLD, and guidelines for the management of NAFLD are less established. However, the field of drug development in NAFLD has witnessed a revolution over the past 5 years with the establishment of a regulatory pathway for Food and Drug Administration approval; this has generated substantial interest from pharmaceutic...Continue Reading

References

May 29, 1999·Gastroenterology·C A MatteoniA J McCullough
Mar 20, 2004·Journal of Hepatology·Stephen H Caldwell, Deborah M Crespo
May 26, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·David E KleinerUNKNOWN Nonalcoholic Steatohepatitis Clinical Research Network
Jan 8, 2009·Physiological Reviews·Philippe LefebvreBart Staels
Aug 14, 2009·Expert Review of Gastroenterology & Hepatology·Naim AlkhouriAriel E Feldstein
Apr 15, 2010·JAMA : the Journal of the American Medical Association·Olivia J PhungCraig I Coleman
Apr 30, 2010·The New England Journal of Medicine·Arun J SanyalUNKNOWN NASH CRN
Oct 1, 2010·The New England Journal of Medicine·Giovanni TargherEnzo Bonora
Oct 20, 2010·Alimentary Pharmacology & Therapeutics·M O RakoskiH Conjeevaram
Apr 28, 2011·JAMA : the Journal of the American Medical Association·Joel E LavineUNKNOWN Nonalcoholic Steatohepatitis Clinical Research Network
May 12, 2012·Endocrinology and Metabolism Clinics of North America·Jack L Leahy
Aug 16, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mattias EkstedtRolf Hultcrantz
Feb 25, 2015·Immunology and Cell Biology·Irina KufarevaTracy M Handel
Sep 18, 2015·Seminars in Liver Disease·Vi Nguyen, Jacob George
Jan 23, 2016·Nature Reviews. Drug Discovery·Giovanni MussoRoberto Gambino
Mar 15, 2016·Gastroenterology·Guillaume LassaillyPhilippe Mathurin
Mar 24, 2016·Digestive Diseases and Sciences·George Boon-Bee Goh, Arthur J McCullough
Aug 9, 2016·Expert Opinion on Emerging Drugs·Mazen NoureddinRohit Loomba
Nov 28, 2016·Gastroenterology·Donna L WhiteHashem B El-Serag
Jan 17, 2017·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Arianna MazzottiGiulio Marchesini
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Feb 28, 2017·JAMA Internal Medicine·Giovanni MussoRoberto Gambino
Mar 2, 2017·JAMA : the Journal of the American Medical Association·Jane E B Reusch, JoAnn E Manson
Aug 24, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Scott L FriedmanEric Lefebvre
Sep 12, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Rohit LoombaUNKNOWN GS-US-384-1497 Investigators

❮ Previous
Next ❯

Citations

Jan 10, 2019·Annual Review of Pharmacology and Toxicology·Leigh GoedekeGerald I Shulman
Jan 3, 2019·Journal of Gastroenterology and Hepatology·Hideki FujiiUNKNOWN Japan Study Group of Nonalcoholic Fatty Liver Disease
Jul 30, 2019·Expert Review of Gastroenterology & Hepatology·Marco ArreseJuan Pablo Arab
Mar 18, 2020·Liver International : Official Journal of the International Association for the Study of the Liver·Federico SalomoneIvo Boškoski
Jan 24, 2019·World Journal of Gastroenterology : WJG·Naoki TanakaEiji Tanaka
Jun 4, 2020·International Journal of Molecular Sciences·Hideki Fujii Japan Study Group Of Nafld Jsg-Nafld
May 8, 2019·Hepatology Communications·Naim AlkhouriMazen Noureddin
Aug 18, 2020·Cardiovascular Endocrinology & Metabolism·Gerardo Rodriguez-Araujo
May 14, 2019·BioMed Research International·Xu LiPujun Gao
Nov 22, 2020·Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology·Amandeep SinghNaim Alkhouri

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
biopsy

Clinical Trials Mentioned

NCT02548351
NCT02704403
NCT03028740
NCT03053050
NCT03053063

Software Mentioned

STELLAR

Related Concepts

Related Feeds

Auditory Perception

Auditory perception is the ability to receive and interpret information attained by the ears. Here is the latest research on factors and underlying mechanisms that influence auditory perception.